SPONSORED CONTENT by Ross Halsne

It’s becoming increasingly difficult for Covered Entities (CEs) to effectively manage their 340B pharmacy programs.  Often times understaffed relative to the task of handling the myriad of challenges that come with managing a 340B program, they face a seemingly constant barrage of maneuvering and attacks aimed at reducing their 340B benefit.  In response, many Covered Entities are evaluating new strategies to strengthen or reinvigorate

25% – 35%
of a hospital’s contract pharmacy opportunity lies in referral prescriptions

There are several ways to enhance, boost, and optimize 340B savings. This white paper looks at how capturing referrals can benefit a covered entity’s 340B program savings and mission.

HRSA GUIDELINES REGARDING REFERRALS

According to HRSA guidelines, a covered entity may send a patient to an outside clinic not registered with 340B and consider

SPONSORED CONTENT

Do you provide clinical care for patients living with or at risk of HIV? If so, you know how important it is to consider their needs beyond the clinic visit.

The patient journey is not linear. Social stigma, family issues, mental health challenges, financial hardship,

SPONSORED CONTENT

Acentrus Specialty hosted its first Acentrus Specialty Conference on January 12-13, 2021, which brought together pharmacists, manufacturers, and suppliers to examine the challenges, opportunities, and best practices in advancing health system specialty pharmacy practice. A pharmacy paradigm shift is under way, as Integrated Delivery Networks (IDNs) are partnering to grow their specialty pharmacy operations.

“The conference highlighted the collaborative potential of our client network,” says George Zula,